Embecta (EMBC) Stock: Buy, Sell, or Hold?
EMBC - Embecta Corp. Common Stock
$5.79
0.13 (2.30%)
▲
5d:
+3.02%
30d:
+10.29%
90d:
+72.84%
WAIT
LOW Confidence
Analysis Updated: Oct 1, 2026 12:00 AM ET
Earnings: Nov 24, 2026
Get Alerted When EMBC Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: EMBC shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: EMBC shows conflicting indicators. Wait for confirmation before entering.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$5.10
Based on 0.0% avg growth
INTRINSIC VALUE TODAY
$3.17
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 2.9x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: EMBC is currently trading at $5.79, which is considered extended relative to its 30-day fair value range of $5.03 to $5.69. From a valuation perspective, the stock is trading at a premium (Forward PE: 3.3) compared to its historical average (2.9). At these levels, the market is pricing in 3.7% annual earnings growth.
Technical Outlook: Technically, EMBC is in a strong uptrend. Immediate support is located at $5.09, while resistance sits at $5.98.
Market Sentiment: EMBC scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. However, the stock is trading significantly above the average Wall Street target of $4.00. Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, EMBC is in a strong uptrend. Immediate support is located at $5.09, while resistance sits at $5.98.
Market Sentiment: EMBC scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. However, the stock is trading significantly above the average Wall Street target of $4.00. Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$5.03 -
$5.69
Company Quality Score
35/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
22.4%
All Signals
- BEARISH: Price extended above range
- BEARISH: Weak technical setup (0/100)
- BULLISH: High volume confirmation
- BEARISH: Trading 30.9% above Wall St target ($4.00)
- BULLISH: Expecting earnings turnaround to 3.7% growth with -8.1% revenue growth
- WARNING: Composite score 34/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$5.03 -
$5.69
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$5.09
Resistance Level
$5.98
Current Trend
Strong Uptrend
Technical data as of
Oct 1, 2026
Fundamental Context
Forward P/E (Next Year Est.)
3.29
Wall Street Target
$4.00
(-30.9%)
Revenue Growth (YoY)
-8.1%
Earnings Growth (YoY)
-53.7%
Profit Margin
8.6%
Valuation Premium vs History
+3.7% premium
PE vs Historical
3.3 vs 2.9
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+3.7%
(market-implied from PE analysis)
1-Year Target
$6.00
(+4%)
2-Year Target
$6.23
(+8%)
3-Year Target
$6.46
(+12%)
3-Yr Target (if PE normalizes)
(PE: 3→3)
PE COMPRESSION
$5.70
(-2%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.4, Growth: -4.0%)
$31.86
(+450%)
Base:
(SPY PE: 3.3, Growth: -4.0%)
$5.13
(-11%)
Bear:
(PE: 2.8, Growth: -4.0%)
$4.36
(-25%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (4x PE), but valuation improves significantly next year (3x PE) as earnings recover.
Trailing PE: 3.93 | Current EPS (TTM): $1.44
Bull Case
$7.62
(+32%)
Analyst growth 22.4%, PE expands to 4.3
Base Case
$6.93
(+20%)
Market implied 22.4%, PE stable at 3.9
Bear Case
$3.85
(-34%)
Severe decline -20.0%, PE contracts to 3.3
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: October 01, 2026 7:04 PM ET
Data refreshes hourly during market hours. Next update: 8:04 PM
Data refreshes hourly during market hours. Next update: 8:04 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is EMBC showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Medical Instruments & Supplies Stocks
Top-rated stocks in Medical Instruments & Supplies by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALC
Alcon AG |
STRONG BUY
27 analysts |
$84 | 50 HOLD |
|
ISRG
Intuitive Surgical Inc |
BUY
33 analysts |
$476 | 33 SELL |
|
RMD
ResMed Inc |
BUY
19 analysts |
$250 | 62 BUY |
|
COO
The Cooper Companies, Inc |
BUY
19 analysts |
$66 | 58 HOLD |
|
WST
West Pharmaceutical Serv… |
STRONG BUY
13 analysts |
$408 | 52 HOLD |
